OBJECTIVES: Levetiracetam is an anticonvulsive drug increasingly used in paediatric populations. Ontogenesis may alter its pharmacokinetics, demanding dose individualisation of levetiracetam in paediatric populations. We therefore aimed to explore levetiracetam pharmacokinetics and to propose its optimal dosing in the paediatric population. METHODS: Individual levetiracetam pharmacokinetic parameters were calculated based on therapeutic drug monitoring data, using a one-compartmental model, and regression models were used to explore possible covariates. RESULTS: 56 patients aged from 47 days to 18 years were included in the analysis. The median (IQR) volume of distribution and clearance of levetiracetam were 0.7 (0.58-0.85) L/kg and 0.123 (0.085-0.167) L/hour/kg, respectively. Levetiracetam pharmacokinetics were influenced by postnatal age, body size descriptors and renal functional status. CONCLUSIONS: Based on observed relationships, an individualised loading dose of 26.2 mg/kg body weight and maintenance dose of 20.7 mg/mL/min of estimated glomerular filtration rate were calculated as optimal. Since we observed increased levetiracetam clearance in association with valproate co-medication, caution should be used when combining these two drugs.

Department of Pediatrics and Inherited Metabolic Disorders 1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czech Republic

Department of Pharmacology 1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czech Republic

Department of Physiology and Pharmacology Karolinska University Hospital Stockholm Sweden

Intensive Care and Department of Pediatric Surgery Erasmus University Medical Center Sophia Children's Hospital Rotterdam Netherlands

Zobrazit více v PubMed

Verrotti A, D'Adamo E, Parisi P, et al. . Levetiracetam in childhood epilepsy. Paediatr Drugs 2010;12:177–86. 10.2165/11316250-000000000-00000 PubMed DOI

Mruk AL, Garlitz KL, Leung NR. Levetiracetam in neonatal seizures: a review. J Pediatr Pharmacol Ther 2015;20:76–89. 10.5863/1551-6776-20.2.76 PubMed DOI PMC

Liu B-K, Jiang L, Li X-J, et al. . Efficacy and safety of levetiracetam in the off-label treatment of neonatal seizures. Int J Neurosci 2020;130:336–42. 10.1080/00207454.2019.1687469 PubMed DOI

Jarvie D, Mahmoud SH. Therapeutic drug monitoring of levetiracetam in select populations. J Pharm Pharm Sci 2018;21:149s–76. 10.18433/jpps30081 PubMed DOI

Tan J, Paquette V, Levine M, et al. . Levetiracetam clinical pharmacokinetic monitoring in pediatric patients with epilepsy. Clin Pharmacokinet 2017;56:1267–85. 10.1007/s40262-017-0537-1 PubMed DOI

Sourbron J, Chan H, Wammes-van der Heijden EA, et al. . Review on the relevance of therapeutic drug monitoring of levetiracetam. Seizure 2018;62:131–5. 10.1016/j.seizure.2018.09.004 PubMed DOI

Carlow DC, Shi H, Schofield RC. Simultaneous quantitation of lamotrigine, levetiracetam, 10-hydroxycarbazepine, topiramate, and zonisamide in serum using HPLC-MS/MS. Methods Mol Biol 2016;1383:29–37. 10.1007/978-1-4939-3252-8_4 PubMed DOI

Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am 1987;34:571–90. 10.1016/S0031-3955(16)36251-4 PubMed DOI

Haycock GB, Schwartz GJ, Wisotsky DH. Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults. J Pediatr 1978;93:62–6. 10.1016/S0022-3476(78)80601-5 PubMed DOI

Pellock JM, Glauser TA, Bebin EM, et al. . Pharmacokinetic study of levetiracetam in children. Epilepsia 2001;42:1574–9. 10.1046/j.1528-1157.2001.41300.x PubMed DOI

Bonett DG, Price RM. Statistical inference for a linear function of medians: confidence intervals, hypothesis testing, and sample size requirements. Psychol Methods 2002;7:370–83. 10.1037/1082-989X.7.3.370 PubMed DOI

Šíma M, Pokorná P, Hronová K, et al. . Effect of co-medication on the pharmacokinetic parameters of phenobarbital in asphyxiated newborns. Physiol Res 2015;64:S513–9. 10.33549/physiolres.933213 PubMed DOI

Jung YS, Lee SM, Park MS, et al. . Population pharmacokinetic model of levetiracetam in Korean neonates with seizures. Int J Clin Pharmacol Ther 2018;56:217–23. 10.5414/CP203058 PubMed DOI

MacDonald KD, Hart KA, Davis JL, et al. . Pharmacokinetics of the anticonvulsant levetiracetam in neonatal foals. Equine Vet J 2018;50:532–6. 10.1111/evj.12790 PubMed DOI

Kim M-J, Yum M-S, Yeh H-R, et al. . Pharmacokinetic and pharmacodynamic evaluation of intravenous levetiracetam in children with epilepsy. J Clin Pharmacol 2018;58:1586–96. 10.1002/jcph.1282 PubMed DOI

Lima-Rogel V, López-López EJ, Medellín-Garibay SE, et al. . Population pharmacokinetics of levetiracetam in neonates with seizures. J Clin Pharm Ther 2018;43:422–9. 10.1111/jcpt.12658 PubMed DOI

Glauser TA, Mitchell WG, Weinstock A, et al. . Pharmacokinetics of levetiracetam in infants and young children with epilepsy. Epilepsia 2007;48:1117–22. 10.1111/j.1528-1167.2007.01090.x PubMed DOI

Egunsola O, Choonara I, Sammons HM. Safety of levetiracetam in paediatrics: a systematic review. PLoS One 2016;11:e0149686. 10.1371/journal.pone.0149686 PubMed DOI PMC